Abstract
The purpose of the study: determination of ALK gene status (mutation) in patients with stage TI-II adenocarcinoma in the relationship with survival, stage, size, metastases in bronchopulmonary lymph nodes and the amplification of Her2/Neu. Materials. 98 stage I-II adenocarcinoma patients. Cases with a mutation in ALK account for 20 (4.8% without randomization). There was used the immunohistochemical method and in situ hybridization. Results. The survival rate of adenocarcinoma patients with metastases in the lymph nodes was lower than in cases without metastases: 8.3 ± 7.8% and 40.9 ± 13% respectively. None of patients with a mutation ALK lived up to 9 years in contrast to the cases without mutations (37.4 ± 12.6%). In the presence of amplification of the Her2 gene survival rate in adenocarcinoma patients was lower if compared to cases without amplification (p = 0.02). Correlation between ALK mutation and amplification of Her2 with increased N is not revealed. Thus, an independent criterion of the prognosis for cases with of stage I-II lung adenocarcinoma is the N index (χ2 = 9.6, p = 0.001). The rate of mutation of ALK was lower, but had the second largest impact on the prognosis (χ2 = 7.7, p = 0.005).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
